Japan Lifeline Co., Ltd.

Tokyo Stock Exchange 7575.T

Japan Lifeline Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2024: USD 83.70 M

Japan Lifeline Co., Ltd. Cash and Short-Term Investments is USD 83.70 M for the year ending March 31, 2024, a -39.42% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Japan Lifeline Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2023 was USD 138.17 M, a 4.74% change year over year.
Japan Lifeline Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2022 was USD 131.92 M, a 6.57% change year over year.
Japan Lifeline Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2021 was USD 123.78 M, a 39.31% change year over year.
Japan Lifeline Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2020 was USD 88.85 M, a 22.87% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 7575.T

Japan Lifeline Co., Ltd.

CEO	Mr. Keisuke Suzuki
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	Tennoz Ocean Square
Employees	1,216
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

Japan Lifeline Co., Ltd., a medical device company, develops, produces, imports, distributes, and trades in cardiovascular related medical devices in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, and radio-frequency transseptal needles. Its cardiovascular and endografting products consist of vascular and open stent grafts, and abdominal stent-grafts; and transvascular intervention products include PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and atrial septal defect closure devices. The company offers gastrointestinal intervention products that consist of radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years